Development of a 1-concentration-4-step dosimeter protocol for methacholine testing  by Merget, Rolf et al.
Respiratory Medicine (2009) 103, 607e613ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedDevelopment of a 1-concentration-4-step dosimeter
protocol for methacholine testingRolf Merget a,*, Rudolf A. Jo¨rres b, Evelyn Heinze a, Michael G. Haufs a,
Dirk Taeger a, Thomas Bru¨ning aa BGFA - Research Institute of Occupational Medicine, Bu¨rkle-de-la-Camp-Platz 1, German Social Accident Insurance,
Ruhr-University, D-44789 Bochum, Germany
b Institute and Outpatient Clinic for Occupational and Environmental Medicine, Ludwig-Maximilians-University
Munich, Germany
Received 9 June 2008; accepted 13 October 2008
Available online 17 November 2008KEYWORDS
Bronchial
hyperresponsiveness;
Concentration;
Doseeresponse-slope;
Dosimeter;
Methacholine;
Protocol* Corresponding author. Tel.: þ49 (0
E-mail address: merget@bgfa.de (
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2008.10.010Summary
Methacholine testing is an important diagnostic tool for asthma. Newly available dosimeter and
software technology allows for simplification of the test. This study aimed to evaluate a single-
concentration dosimeter protocol for methacholine testing by comparison with a multi-
concentration dosimeter protocol similar to that recommended by the American Thoracic
Society (ATS) (standard protocol).
Fifty young subjects with high pretest probability for bronchial hyperresponsiveness under-
went two challenges in randomized order within one week. The novel protocol used a Medic-
Aid Sidestream nebulizer and a fixed methacholine concentration of 16 mg/mL. Number and
duration of nebulizations were matched to the last four doses of the standard protocol, and
results were expressed cumulatively.
The rank correlation between log slopes (nZ 50) was 0.86; that between log provocative
doses (nZ 18), which differed at low values, was 0.58. When requiring a 20% fall in FEV1 at
any methacholine dose, 18 subjects were hyperresponsive and 28 normoresponsive in both
tests (46/50 concordant). One subject was positive only with the standard, and 3 only with
the novel protocol (Cohen’s kappa 83%).
The novel protocol for methacholine testing yielded qualitative results similar to those of
the ATS multi-concentration protocol, although there were quantitative differences at low
doses. However, its design and handling may offer advantages for clinical practice.
ª 2008 Elsevier Ltd. All rights reserved.) 23 43 02 45 46; fax: þ49 (0) 23 43 02 45 42.
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The assessment of bronchial hyperresponsiveness (BHR)
is in widespread use for clinical, clinical-experimental
and epidemiological purposes. Based on available
methacholine (MCH) challenge protocols, the American
Thoracic Society (ATS) proposed a specific dosimeter
method involving the administration of five increasing
concentrations.1 Despite all efforts for standardization,
there are, however, still various methods in use. Among
the reasons for this seems to be the intention to simplify
the procedure, or the fact that some nebulizers, in
particular the DeVilbiss 646 included in the ATS
protocol, show weaknesses2 that require appropriate
measures.3
One of the points of concern in clinical practice is the
use of multiple concentrations as required by most
challenge protocols. The preparation of various concen-
trations needs equipment and is a potential source of
error, variability and safety concerns. Conversely, the
development of a single-concentration protocol is
handicapped by the prohibitive increase in the number
of inhalations required to cover the standard ranges of
MCH doses. However, current technology allows for
additional modification of the nebulization time without
changing the basic output rate, and implementation into
software renders the use of complex nebulization
schemes easy.
It was the aim of this study to develop a single-
concentration protocol that covers the required dose range
and as closely as possible matches the doses administered
in the ATS multi-concentration method. We compared the
results of both procedures with regard to the dichotomous
outcome of the presence versus absence of BHR, as well as
quantitative measures of response, in a population of
subjects with a high pretest probability of BHR.
Material and methods
Study subjects
Fifty-six subjects were recruited from medical students.
All answered at least one question of the ATS ques-
tionnaire1 affirmatively (physician-diagnosed asthma
ever; hospitalized for asthma ever; (chronic or recur-
rent) respiratory disease as a child; asthma symptoms
within the last two weeks). Three subjects did not
perform the second challenge, and three were excluded
due to inacceptable spirometry. Thus, the final pop-
ulation comprised 50 subjects (22 females; median age
25, range 22e44 years; median FEV1 101.9, range 73.9e
145.7% predicted (baseline of standard protocol) and
103.9, range 81.1e139.3% predicted (baseline values of
novel protocol)). All subjects denied to have experi-
enced a lower respiratory tract infection within 6 weeks
prior to measurements. None of them showed one of the
accepted contraindications of MCH challenge or a medi-
cation that is considered to influence the results. The
study was approved by the Ethics Committee of the
Ruhr-University and all subjects gave their informed
consent.Study design
Subjects participated in the two challenges in randomized
order within one week. Tests were done between 8 a.m.
and 3 p.m., paying attention to performing both challenges
in one individual at comparable times of the day (median
time interval 65, interquartile range 20e146 min).
Methods
Standard protocol according to ATS
The protocol used for comparison was based on the
dosimeter protocol recommended by the ATS.1 This
involves five concentrations administered in five steps by
a DeVilbiss 646 nebulizer (DeVilbiss, Malsch, Germany),
without initial inhalation of the diluent (Table 1). Each
concentration was given in five consecutive slow inspira-
tions from functional residual to near total lung capacity,
while the nebulizer was actuated over 0.6 s. Inspiratory
airflow was kept close to 1 L/s by observation of a visual
scale. The time interval between consecutive steps was
5 min, with a range from 4 to 6 min in single subjects.
Spirometry was performed at baseline as well as 90 s after
inhalation of each concentration. At baseline and after the
last step spirometry comprised three acceptable manoeu-
vres, whereas only one acceptable manoeuvre was required
after the other steps.
Compared to the ATS protocol,1 three minor modifica-
tions were incorporated. Firstly, the nebulizer was actu-
ated 0.5 s after the start of inspiration to ensure
a significant airflow upon nebulization. Secondly, we
omitted breathholds after inhalation to facilitate compa-
rability, as these were considered unfeasible in the novel
protocol comprising a greater number of consecutive
inhalations. Thirdly, spirometry was performed at only one
time point, as prior to spirometry bodyplethysmography
was done (data not shown). This protocol is called standard
protocol throughout the manuscript. The end-of-test
criterion was either a 20% fall in FEV1 compared to
baseline or having reached the highest concentration of
MCH.
MCH (Synopharm, Barsbu¨ttel, Germany) was diluted with
isotonic saline. Nebulizations were performed by an APSpro
dosimeter (Viasys Healthcare, Ho¨chberg, Germany) and the
nebulizer filled with 2 mL solution. The straw of the nebu-
lizer had been fixed4 to minimize the previously reported
variability of output2; the output was 9 mL per actuation.
Novel single-concentration protocol
Based on the nominal output of the DeVilbiss 646 nebulizer
(900 mL/min), the number of 5 inhalations of 0.6 s duration
and the increasing concentrations of the standard protocol,
the dose delivered at each step was computed (Table 1).
We merged the lowest two concentrations into a single
equivalent concentration. Using the nominal output of the
Medic-Aid Sidestream nebulizer (240 mL/min; Viasys
Healthcare, Ho¨chberg, Germany) that was utilized in this
protocol and the fixed MCH concentration of 16 mg/mL,
a scheme of nebulization times and numbers was developed
(Table 2) that comprised the same dose sequence as the
standard protocol (Table 1). The Medic-Aid nebulizer was
Table 1 Five-concentration-5-step dosimeter protocol according to the American Thoracic Society. The output of the De-Vilbiss
646 nebulizer used in the calculations was 900 mL/min.
Step no Nebulization time
per breath (s)
No of
breaths (n)
MCH concentration
(mg/mL)
MCH dose (mg) Cumulative MCH
dose (mg)
1 0.6 5 0.0625 3 3
2 0.6 5 0.25 12 15
3 0.6 5 1 45 60
4 0.6 5 4 180 240
5 0.6 5 16 720 960
MCHZmethacholine, nZ number.
Dosimeter protocol for methacholine testing 609combined with the electronic, software-controlled APSpro
dosimeter (Viasys Healthcare) that ensured a reliable
switching of the number and duration of nebulizations
within the procedure.
As provocative substance we used MCH solved in phos-
phate-buffered saline (Provokit; Lindopharm, Hilden,
Germany). As in the standard procedure, nebulization was
initiated 0.5 s after start of each of the consecutive slow
inspirations to near total lung capacity, without breath-
hold, and spirometry was performed 90 s after inhalation.
Quality control
All tests were performed under comparable conditions in
a climate room at 24 C and a relative humidity of 50%.
Nebulizer outputs were assessed weekly by weighing.1
There were no trends towards increasing or decreasing
outputs over time, and in nearly all measurements the
output was within 10% of the nominal value of the nebu-
lizers, as recommended.1 All spirometric measurements
were examined by trained technicians and had to fit
acceptability criteria.5 Overall, 84% of repeated baseline
measurements, and 81% of repeated measurements per-
formed at the last dose administered, met both the FEV1
and FVC reproducibility criteria.
Analysis
For each challenge, PD20FEV1 was derived by linear inter-
polation, whereby doses were plotted logarithmically and
responses linearly.1 In tests with a positive response at the
first step, a virtual initial dose of 0.1 mg MCH was assumed
to calculate a provocative dose. As an alternative measure
which allowed to quantify also challenges in which a 20%
fall in FEV1 was not achieved, the slope of the dosee
response curve was calculated.6Table 2 Novel single-concentration-4-step dosimeter protocol.
was 240 mL/min.
Step no Nebulization time
per breath (s)
No of breaths (n) MC
(m
1 0.234 1 16
2 0.352 2 16
3 0.563 5 16
4 0.865 13 16
MCHZmethacholine, nZ number.Data analyses were performed using log-transformed
(base 10) slopes for all subjects and log-transformed (base
10) PD20FEV1 for those showing a 20% fall in FEV1 in both
tests. Correspondingly, geometric mean values and stan-
dard deviations (SD) were computed, geometric SD being
expressed as dimensionless variability factor. To quantify
the agreement between values, Spearman’s rank correla-
tion coefficients (rs) were calculated, and log values were
compared by the t-test for paired samples. Additionally,
standard linear regression analysis was performed. In
scatter plots orthogonal regression lines are depicted, and
approximate confidence intervals are given in the respec-
tive figure legends. We also performed a Bland & Altman
analysis7 to elucidate the relationship between the values
by the two protocols. The agreement of the binary classi-
fication according to different cut-off doses of BHR1 was
tested by Cohen’s kappa.8 Statistical significance was
assumed if p< 0.05, and 95%-confidence intervals (95%-CI)
were given where appropriate. All analyses were performed
using the statistical package SAS 9.1 (Cary, NC, USA).
Results
All subjects tolerated both challenge protocols well. One
subject showed a 29% fall in FEV1 from baseline after
inhalation of the initial dose of 15 mg MCH of the novel
protocol, and a 32% decrease after inhalation of 3 mg MCH
of the standard protocol. A second subject showed a 27%
fall in FEV1 after the second step of the standard protocol.
All other 20% FEV1 decreases occurred at doses >15 mg
MCH with both protocols. The mean (SD) maximal fall in
FEV1 at the end of the test was 15.8 (10.0)% from baseline
with the standard protocol and 15.5 (9.3)% with the novel
protocol.The output of the Medic-Aid nebulizer used in the calculations
H concentration
g/mL)
MCH dose
(mg)
Cumulative MCH dose
(mg)
15 15
45 60
180 240
720 960
Geometric mean PD20FEV1 of standard and
novel protocol (µg)
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Figure 2 BlandeAltman plot of (log) PD20FEV1 as assessed by
the novel and the standard protocol. The vertical axis repre-
sents the differences in log PD20FEV1 (standard minus novel
protocol) expressed in doubling doses and the horizontal axis
their geometric mean value.
610 R. Merget et al.Geometric mean (geometric SD) of PD20FEV1 was 78
(6.8) mg for the standard protocol and 113 (3.7) mg for the
novel protocol; these values were not significantly different
(pZ 0.21). Mean PD20FEV1 was greater by 0.53 (95%-CI
0.33 to 1.4) doubling doses in the novel compared to the
standard protocol. Geometric mean (SD) of log slopes was
22.9 (6.2) and 21.7 (5.5)%/mg which was not significantly
different from each other (pZ 0.68).
Log PD20FEV1 of both protocols correlated with each
other (nZ 18, rsZ 0.58, pZ 0.0122; Fig. 1). Regression
analysis (novel versus standard protocol) yielded a slope of
0.53 (95%-CI 0.30e0.76) and an intercept of 0.36 (0.67
to 0.04). If PD20FEV1 values 15 mg (nZ 2) were omitted,
the slope was 0.42 (95%-CI 0.11e0.74) and the intercept
0.45 (0.79 to 0.10). The Bland & Altman plot (Fig. 2)
indicated that the difference between PD20FEV1 values
depended on their magnitude, in agreement with the fact
that the slope was significantly different from one.
Log slopes showed a mean difference between novel and
standard protocol of 0.05 (95%-CI of 0.03 to 0.21). There
was a correlation between log slope (rsZ 0.86, p< 0.0001;
Fig. 3), whereby the linear regression line showed a slope of
0.80 (95%-CI 0.67e0.94) and an intercept of 0.25 (0.04e
0.46). The respective Bland & Altman plot (Fig. 4) indicated
that the difference between slopes did not depend on their
magnitude.
If BHR was defined by a 20% fall in FEV1 after any dose
of MCH, 18 subjects were rated as positive and 28 as
negative in both tests (46/50 concordant). One subject was
positive only with the standard protocol and three only with
the novel protocol (Cohen’s kappa of 83% (95%-CI 68e99%)).PD20FEV1 [µg] of standard protocol
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Figure 1 PD20FEV1 as assessed by the novel and the standard
protocol. The dotted horizontal and vertical lines represent
a dose of 960 mg MCH (maximum cumulative value in both
tests). The dashed horizontal and vertical lines represent
a dose of 240 mg MCH. The heavy straight line represents the
orthogonal regression line of those test results in which
PD20FEV1 could be determined. The dotted lines along the
diagonal indicate a band of width 2 doubling doses around the
line of identity.If a 20% fall in FEV1 after cumulative doses of 240 mg
was required, 11 subjects were rated as positive in both
tests and 36 as negative (47/50 concordant). Three subjects
were positive only with the novel protocol (Cohen’s kappa
of 84% (95%-CI 67e100%)).
Discussion
The present study demonstrated a reasonable agreement
between a novel single-concentration dosimeter protocol
for MCH testing and a standard multi-concentration
protocol. This was true for dose response slopes as well as1
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Figure 3 Log slopes of the doseeresponse curves of the two
protocols according to O’Connor et al.6 The line represents the
orthogonal regression of the novel to the standard protocol (in
log10-domain: slope 0.91 (95%-CI 0.55e1.28), intercept 0.09
(0.46 to 0.65); nZ 50). Values for which pairs of PD20FEV1
(see Fig. 1) could be computed at least for one test are marked
as closed symbols.
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Figure 4 BlandeAltman plot of the log slopes of the dose
response curves of the novel and the standard protocol. The
vertical axis represents the differences in slope (standard
minus novel protocol) and the horizontal axis their mean value.
Values for which pairs of PD20FEV1 (see Fig. 1) could be
computed at least for one test are marked as closed symbols.
Dosimeter protocol for methacholine testing 611for the recognition of BHR by different cut-off values of
provocative doses. At low values, however, provocative
doses differed between both methods.
To evaluate the novel method, we referred to a newly
designed multi-concentration dosimeter protocol recom-
mended by the ATS,1 similar to those used previously.9,10 As
multiple concentrations involve potentially time-consuming
and error-prone dilution steps, we aimed at developing
a single-concentration protocol the doses of which closely
matches those of the ATS protocol. This protocol should be
as simple as possible in its practical use, by delegating the
major technical issues involved to the software control of
the nebulizer.
The nebulization scheme required for this was derived
from a comparison of nebulizer outputs. To our knowledge,
data on the aerosol output of the DeVilbiss 646 for short
actuation are not available. In the Medic-Aid nebulizer11
the output at short actuation corresponded to 64e85 mL/
min, about half the reported steady-state value (160 mL/
min). Using nebulization durations of 0.6 s and 10 actua-
tions we recorded a weight loss of 240 mL/min 10% when
using the pressure-stabilized APSpro dosimeter at a pres-
sure of 1.3 105 Pa and a flow of 9.6 L/min. Among the
reasons for the differences in output might be a lower
driving pressure or the lower filling volume of 1 mL used
previously.11 Determination of aerosol output by weight
might be affected by condensate, if subjects exhale
through the nebulizer (see 12). As this is unlikely to affect
the actual output, the variability of 10% was probably an
upper bound for the true variability. Clearly, determina-
tions of aerosol output cannot substitute for a comparative
study, as biological and technical doses can differ and
results are not predictable solely from technical data.11
While we used MCH chloride and isotonic saline in the
standard method, the single-concentration protocol
involved a commercially available solution of MCH chloride
in phosphate-buffered saline. Both solutions were matched
with regard to MCH content. Saline was chosen to achieve
comparability with ATS recommendations.1 In contrast, the
substance approved by German authorities for routineinhalation challenges is that solved in phosphate-buffered
saline. We considered it unwise not to use this in the novel
protocol especially designed for clinical practice, as well as
for pharmacological trials. There seem to be no published
data on a comparison of MCH formulations, but effects of
diluents should have been related to ionic composition
and/or pH, which, however, are not likely to play a role at
the low amounts of fluid delivered. It is therefore unlikely
that the use of different MCH sources, while matching the
amount of active substance, has considerably influenced
our results, especially the differences between provocative
doses.
In both protocols the amount of MCH was expressed as
cumulative dose. By the nature of its design the novel
protocol favours a cumulative evaluation, whereas the ATS
preferred provocative concentrations to facilitate calcula-
tions.1 Even more, the novel protocol required physiolog-
ical cumulation of inhalations within the short time interval
(1 min) of one dose step. The fact that there was a dosee
response allowing to compute PD20FEV1 values showed this
assumption to be satisfied. With regard to data evaluation,
non-cumulative concentrations and cumulative doses are
linearly related to each other, and the choice between
them amounts to a rescaling of results. Thus the relation-
ships illustrated in Figs. 1 and 3 are essentially unaffected
by choosing cumulative versus non-cumulative evaluation.
An issue different from that regarding the expression of
results is the physiological cumulation of MCH effects which
depends on the time between subsequent inhalations. We
kept this time interval as close as possible to 5 min in both
protocols. The sources of minor variation (1 min)
encountered in single patients were of technical nature and
are unlikely to have influenced the results. For example,
assuming a 20% cumulation of doses at 5-min intervals and
an exponential decay of this effect, a variation of 1 min
would lead to a change in effective dose of less than 10%.
The regression line between the values of PD20FEV1 signif-
icantly differed from the line of identity, however in most
patients the difference between these values at least
ranged within two doubling doses of MCH relative to the
regression line (Fig. 1). This was only slightly higher than
the range of 1.5 doubling concentrations considered
acceptable in repeated challenges using the same
protocol.1
Log slopes which could be computed in all subjects were
close to the line of identity even at high degrees of BHR,
and the Bland & Altman plot did not indicate a systematic
difference between the two methods. In contrast, PD20FEV1
showed a difference despite the equivalence of nebulizer
outputs. This, however, did not seem to affect the recog-
nition of BHR, which we consider as a major result. The fact
that the relationship of log slopes to each other and that of
PD20FEV1 values at low but not at high doses differed,
suggests a difference in the shape of doseeresponse
curves. To explain the differences, one might try to invoke
potential differential effects of MCH concentration and
cumulation. At all steps except the last one, MCH concen-
tration was higher in the novel compared to the standard
protocol. If concentration within aerosol particles, in
addition to total dose, was of importance, there should
have been stronger responses, i.e. lower PD20FEV1, in the
first steps of the novel protocol, in contrast to the
612 R. Merget et al.observations. Conversely, if degradation of MCH occurred
over the course of the 13 inhalations of the last step, this
should have resulted in a weaker response, i.e. higher
PD20FEV1, again in contrast to the data. Moreover, the
difference between initial doses of the protocols might only
explain discrepancies regarding the two lowest MCH doses.
If the deposited aerosol amounts differed throughout the
whole range, this should have produced a parallel shift
from the line of identity, retaining a slope of one. There-
fore, such effects are unlikely to explain the difference in
PD20FEV1 values.
However, other factors might also have been involved.
As it was not possible to cover the full dose range solely by
variation of nebulization time, the novel protocol
comprised a varying number of deep inhalations. Deep
inspirations can diminish airway resistance after prior
administration of bronchoconstrictor agents.13 Thus the
results of the two protocols might have differed especially
at the last step when the number of inhalations in the novel
procedure was as high as 13. In contrast to this expectation,
PD20FEV1 was comparable at high doses and different at
lower doses at which the number of inhalations was low in
both protocols, even lowest in the novel protocol. Thus, the
assumption of different bronchodilator responses at low
numbers of inhalations (one or two versus five) would also
not explain that PD20FEV1 values of the novel protocol were
elevated at low doses. There remains as the most likely
possibility that short actuation times of the Medic-Aid
device resulted in a lower deposited aerosol fraction rela-
tive to weight. It seems in accordance with this assumption
that PD20FEV1 corresponding to the third step of the novel
and the fourth step of the standard protocol were compa-
rable, both of them being based on five nebulizations of
>0.5 s duration. Thus the differences between PD20FEV1
values appear to emphasize the argument that different
nebulizers or different modes of action of the same nebu-
lizer are difficult to match solely from calculations of their
output, and that empirical comparisons such as the one
presented here are indispensable for the evaluation of
provocation protocols.
The choice of the initial dose in challenge protocols aims
at a balance between safety and feasibility requirements.
When developing the novel protocol we shortened the
standard protocol by merging the first and second step into
a single one. Only one subject showed a 20 fall in FEV1
(32% from baseline) at the lowest dose of the standard
protocol, and about the same response after the first dose
of the novel protocol. In the course of both challenges, lung
function responses were similar. We thus believe that the
novel protocol offers a similar margin of safety as the
standard protocol. Our data extend those of a previous
study14 which compared a single-concentration-seven-step
protocol using 32 mg/mL MCH and the Medic-Aid nebulizer
with a multi-concentration protocol based on the DeVilbiss
646.11 Our method was designed to be shorter and simpler
than this. Due to its easier handling, the single-concentra-
tion protocol was favoured by the technicians compared to
the standard protocol.
Both protocols did not comprise inhalation of the diluent
prior to the first MCH dose. Although often incorporated,
diluent inhalation is not considered mandatory,1 and
obstructive airway responses to diluent are rare. Onereason for inclusion might be to familiarize subjects with
the procedure. However, the participants studied were
cooperative in performing the required manoeuvers. When
implementing the protocol in clinical practice, measuring
untrained patients, an initial diluent inhalation could be
easily added.
In conclusion, the results of our study suggest that - at
least for qualitative purposes such as deciding on the
presence of BHR - a simplification of MCH inhalation chal-
lenges can be achieved by using a single concentration at
varying nebulization times and numbers. The novel protocol
avoided the preparation of different dilutions, which might
be not very feasible for clinical routine in outpatient
clinics. The simplification by using a single concentration
could be achieved by software-controlled nebulization
without introducing additional sources of error. Although
there was a high concordance of both tests with respect to
classification of BHR, there was an unexplained systematic
deviation at low doses that could, however, be described by
a linear regression line. Further studies, possibly using
further improved nebulizers, might achieve complete
quantitative comparability also at low doses.
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